Vertex to Acquire Crinetics Pharmaceuticals in Major Pharma Deal
CRNX sits 63% above its 52-week low of $25.83.
Summary
Vertex Pharmaceuticals has announced its intent to acquire Crinetics Pharmaceuticals for $10 billion, offering $85 a share in cash. This major M&A event follows strong positive news for Crinetics, including European Commission approval for its key drug PALSONIFY, robust Q1 2026 financial results with significant product revenue growth, and positive long-term clinical data presentations for PALSONIFY. The acquisition represents a strategic expansion for Vertex, which anticipates the deal will immediately help revenue growth and contribute to non-GAAP operating income by 2029. Vertex projects Crinetics's PALSONIFY and Atumelnant could potentially add more than $5 billion in combined annual revenue. The deal is expected to fundamentally change Crinetics' investment profile, likely at a premium for its shareholders.
At the time of this announcement, CRNX was trading at $42.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $25.83 to $57.99. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.